ReviewCurrent opinion in hematology2009
Acute graft-versus-host disease: new treatment strategies.
Review in Current opinion in hematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 72 citations in OpenAlex.
- CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Trial
- A digital biomarker dataset from hematopoietic cell transplant caregivers and patients.Scientific data · 2026Article
- Donor regulatory T cells rapidly adapt to recipient tissues to control murine acute graft-versus-host disease.Nature communications · 2024Article
- Anti-Heliyon · 2023Article
- Identification of Potential Treatments for Acute Lymphoblastic Leukemia through Integrated Genomic Network Analysis.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Compound A Increases Cell Infiltration in Target Organs of Acute Graft-versus-Host Disease (aGVHD) in a Mouse Model.Molecules (Basel, Switzerland) · 2021Article
- Promoting Health and Well-Being Through Mobile Health Technology (Roadmap 2.0) in Family Caregivers and Patients Undergoing Hematopoietic Stem Cell Transplantation: Protocol for the Development of a Mobile Randomized Controlled Trial.JMIR research protocols · 2020Article
- Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress.Stem cell research & therapy · 2020Review
- A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma.Cellular & molecular immunology · 2018Article
- Reduction of aGVHD using chicken antibodies directed against intestinal pathogens in a murine model.Blood · 2017Article
- Article
- Hyperglycemia in patients with hematologic malignancies.Current diabetes reports · 2015Review
- Antibody- and aptamer-strategies for GvHD prevention.Journal of cellular and molecular medicine · 2015Review
- Article
- Prevention of graft-versus-host-disease with preserved graft-versus-leukemia-effect by ex vivo and in vivo modulation of CD4(+) T-cells.Cellular and molecular life sciences : CMLS · 2014Article
- Aqueous two-phase system patterning of detection antibody solutions for cross-reaction-free multiplex ELISA.Scientific reports · 2014Article
- Clinical significance of anti-endothelial cell antibody in allogeneic hematopoietic stem cell transplantation recipients with graft-versus-host disease.International journal of hematology · 2014Article
- Electroporation formulation for cell therapy.Methods in molecular biology (Clifton, N.J.) · 2014Article
- Graft-versus-host disease biomarkers: omics and personalized medicine.International journal of hematology · 2013Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewGraft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT), despite improvements in our understanding of its pathophysiology as well as the generation of new monoclonal antibodies, immunomodulatory chemotherapy, cellular therapeutics and supportive care. Herein, we review therapies that have proven effective as well as newer agents that have recently improved GVHD response rates and survival following HCT. RECENT
findingsNovel approaches to prevent or treat GVHD are often based on evidence from experimental models. Our understanding of the pathophysiology of GVHD may lead to the development of innovative strategies that target both soluble and cellular effectors. Among such agents are sirolimus, anti-tumor necrosis factor antibodies, anti-LFA-3-IgG fusion protein, extracorporeal photopheresis, mesenchymal stem cells and regulatory T cells. SUMMARY: Obstacles to the improvement of HCT include the tight linkage between GVHD toxicity and the beneficial graft-versus-leukemia (GVL) effect, as well as the impairment of immune reconstitution by immunomodulatory drugs leading to life-threatening infections. The design of newer phase I/II clinical trials are underway. Future therapies are likely to include modulation of cell types that play key roles in the GVH process, including regulatory T cells, dendritic cells, natural killer T cells and B cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.